

## DAFTAR PUSTAKA

- Abdel-Hafez, M.A., Abou-El-Hana, N.M., Erfan, A.A., El-Gamasy, M., Abdel-Nabi, H. 2017. Predictive risk factors of steroid dependent nephrotic syndrome in children. *J Nephropathol*, 6(3): 180.
- Alatas, H., Trihono, P.P., Tambunan, T., Pardede, S.O., El, H. 2015. Pengobatan terkini sindrom nefrotik (SN) pada anak. *Sari Pediatr*, 17(2): 155–162.
- Albar, H., Bilondatu, F., Daud, D. 2018. Risk factor for relapse in pediatric nephrotic syndrome. *Paediatr Indones*, 58(5): 238–241.
- Ali, S.H., A.twfeek, Z., Azat, N.F.A., Hasan, A.A. 2016. Triggering factors for relapses in steroid sensitive nephrotic syndrome. *IntJCurrMicrobiolAppSci*, 5(8): 842–851.
- Alsaran, K., Mirza, K., Al-talhi, A., Al-kanani, E. 2017. Experience with second line drugs in frequently relapsing and steroid dependent childhood nephrotic syndrome in a large Saudi center. *Int J Pediatr Adolesc Med*, 4(2): 66–70.
- Borovitz, Y., Alfandary, H., Haskin, O., Levi, S., Kaz, S., Davidovits, M., Dagan, A., Haskin, O. 2020. Lower prednisone dosing for steroid-sensitive nephrotic syndrome relapse: A prospective randomized pilot study. *Eur J Pediatr*, 179(2): 279–283.
- Cammas, B., Harambat, J., Bertholet-Thomas, A., Bouissou, F., Morin, D., Guigonis, V., Bendeddouche, S., *et al.* 2011. Long-term effects of cyclophosphamide therapy in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. *Nephrol Dial Transplant*, 26(1): 178–184.
- Chang, J.W., Tsai, H.L., Yang, L.Y., Chen, T.J. 2012. Epidemiology and predictors of end-stage renal disease in Taiwanese children with idiopathic nephrotic syndrome. *J Epidemiol*, 22(6): 517–522.
- Cucer, F., Miron, I., Müller, R., Iliescu Halitchi, C., Mihaila, D. 2010. Treatment with cyclophosphamide for steroid-resistant nephrotic syndrome in children. *Maedica (Buchar)*, 5(3): 167–70.
- Dakshayani, B., Lakshmana, M., Premalatha, R. 2018. Predictors of frequent relapsing and steroid-dependent nephrotic syndrome in children. *Turk Pediatr Ars*, 53(1): 24–30.
- Dorresteyn, E.M., Kist-van Holthe, J.E., Levtchenko, E.N., Nauta, J., Hop, W.C.J., van der Heijden, A.J. 2008. Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome. *Pediatr Nephrol*, 23(11): 2013–2020.
- Downie, M.L., Gallibois, C., Parekh, R.S., Noone, D.G. 2017. Nephrotic syndrome in infants and children: Pathophysiology and management. *Paediatr Int Child*

*Health*, 37(4): 248–258.

- Gellermann, J., Weber, L., Pape, L., Tönshoff, B., Hoyer, P., Querfeld, U. 2013. Mycophenolate mofetil versus cyclosporin a in children with frequently relapsing nephrotic syndrome. *J Am Soc Nephrol*, 24(10): 1689–1697.
- Ginzler, E.M., Dooley, M.A., Aranow, C., Kim, M.Y., Buyon, J., Merrill, J.T., Petri, M., *et al.* 2005. Mycophenolate Mofetil or Intravenous cyclophosphamide for lupus nephritis. *NEJM*, 353(21): 2219–2228.
- Gollapalli, D.R., MacPherson, I.S., Liechti, G., Gorla, S.K., Goldberg, J.B., Hedstrom, L. 2010. Structural determinants of inhibitor selectivity in prokaryotic IMP dehydrogenases. *Chem Biol*, 17(10): 1084.
- Gulati, S., Pokhariyal, S., Sharma, R.K., Elhence, R., Kher, V., Pandey, C.M., Gupta, A. 2001. Pulse cyclophosphamide therapy in frequently relapsing nephrotic syndrome. *Nephrol Dial Transplant*, 16(10): 2013–2017.
- Hidayati, E.L., Pardede, S.O., Trihono, P.P. 2011. Comparison of oral and intravenous cyclophosphamide in children with steroid-resistant nephrotic syndrome. *Paediatr Indones*, 51(5): 266.
- Iriani, Y., Tambunan, T., Sastroasmoro, S. 2016. Cyclophosphamide in frequent-relapsing or steroid-dependent nephrotic syndrome: Review of 38 patients. *Paediatr Indones*, 45(1): 18.
- Jimmy, B., Jose, J. 2011. Patient Medication Adherence: Measures in Daily Practice. *OMJ*, 26(3): 155–159.
- Kari, J.A., Alhasan, K.A., Safder, O.Y. 2020. Rituximab versus cyclophosphamide as first steroid sparing agent in childhood frequently relapsing and steroid dependent nephrotic syndrome. *Pediatr Nephrol*, 35(8): 1445–1453.
- Karunamoorthy, S., Thanigachalam, D., Jeyachandran, D., Ramanathan, S., Natarajan, G., Thoppalan, B. 2019. The safety and efficacy of mycophenolate mofetil in children and adolescents with steroid-dependent nephrotic syndrome: A single-centre study. *Clin Kidney J*, 13(2): 179–183.
- Kruh, J., Foster, C.S. 2012. Corticosteroid-sparing agents: Conventional systemic immunosuppressants. *Dev Ophthalmol*, 51(1): 29–46.
- Kumar, V., Kaminski, H.J. 2011. Treatment of myasthenia gravis. *Curr Neurol Neurosci Rep*, 11(1): 89–96.
- Larkins, N.G., Liu, I.D., Willis, N.S., Craig, J.C., Hodson, E.M. 2020. Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children. *Cochrane Database Syst Rev*, 4(4): CD002290.
- Liu, Y., Yang, R., Yang, C., Dong, S., Zhu, Y., Zhao, M., Yuan, F., *et al.* 2018. Cyclophosphamide versus cyclosporine a therapy in steroid-resistant nephrotic syndrome: A retrospective study with a mean 5-year follow-up. *J Int Med Res*, 46(11): 4506–4517.

- Lugani, F., Angeletti, A., Ravani, P., Vivarelli, M., Colucci, M., Caridi, G., Verrina, E., *et al.* 2021. Randomised controlled trial comparing rituximab to mycophenolate mofetil in children and young adults with steroid-dependent idiopathic nephrotic syndrome: Study protocol. *BMJ Open*, 11(11): 1–7.
- Manalu, E. 2019. Sindrom nefrotik resisten steroid. *J Ilm WIDYA*, 5(3): 1–8.
- Mennella, J.A., Beauchamp, G.K. 2008. Optimizing oral medications for children. *Clin Ther*, 30(11): 2120.
- Motoyama, O., Sakai, K., Itaka, K. 2014. Long-term prognosis of 4 children with steroid-sensitive nephrotic syndrome and relapse after 30 years of age. *CEN Case Reports*, 3(1): 106–109.
- Moudgil, A., Bagga, A., Jordan, S.C. 2005. Mycophenolate mofetil therapy in frequently relapsing steroid-dependent and steroid-resistant nephrotic syndrome of childhood: Current status and future directions. *Pediatr Nephrol*, 20(10): 1376–1381.
- Nunn, T., Williams, J. 2005. Formulation of medicines for children. *Br J Clin Pharmacol*, 59(6): 674.
- Oh, G.J., Waldo, A., Paez-cruz, F., Gipson, P.E., Pesenson, A., Selewski, D.T., Kamil, E.S., *et al.* 2019. Steroid-associated side effects in patients with primary proteinuric kidney disease. *Kidney Int Reports*, 4(11): 1608–1616.
- Özlu, S.G., Demircin, G., Tökmeci, N., Çaltık Yılmaz, A., Aydoğ, Ö., Bülbül, M., Öner, A. 2015. Long-term prognosis of idiopathic nephrotic syndrome in children. *Ren Fail*, 37(4): 672–677.
- Pardede, S.O. 2016. Mikofenolat Mofetil sebagai Terapi Sindrom Nefrotik Relaps Sering dan Resistensi Steroid pada Anak. *Sari Pediatr*, 9(1): 23.
- Rovin, B.H., Adler, S.G., Barratt, J., Bridoux, F., Burdge, K.A., Chan, T.M., Cook, H.T., *et al.* 2021. KDIGO 2021 Clinical practice guideline for the management of glomerular diseases. *Kidney Int*, 100(4): S1–S276.
- Sarker, M., Islam, M., Saad, T., Shoma, F., Sharmin, L., Khan, H., Afrooz, F., Fatmi, L., *et al.* 2020. Risk factor for relapse in childhood nephrotic syndrome -a hospital based retrospective study. *Faridpur Med Coll J*, 7(1): 18–22.
- Seyedzadeh, A., Tohidi, M.R., Rafati, M., Seyedzadeh, M.S., Hookari, S. 2021. Mycophenolate mofetil as a rescue therapy in frequently relapsing/steroid-dependent nephrotic syndrome in children; Ability to maintain remission. *Iran J Kidney Dis*, 15(5): 364–372.
- Sinha, A., Puraswani, M., Kalaivani, M., Goyal, P., Hari, P., Bagga, A. 2019. Efficacy and safety of mycophenolate mofetil versus levamisole in frequently relapsing nephrotic syndrome: An open-label randomized controlled trial. *Kidney Int*, 95(1): 210–218.

- Trihono, P.P., Alatas, H., Tambunan, T., Pardede, S.O. 2016. Konsensus tata laksana sindrom nefrotik idiopatik pada anak. *Unit Kerja Koordinasi Nefrologi IDAI*.
- Wang, J., Mao, J., Chen, J., Fu, H., Shen, H., Zhu, X., Liu, A., *et al.* 2016. Evaluation of mycophenolate mofetil or tacrolimus in children with steroid sensitive but frequently relapsing or steroid-dependent nephrotic syndrome. *Nephrology*, 21(1): 21–27.
- Xiang, X., Qiu, S.Y., Wang, M. 2021. Mycophenolate mofetil in the treatment of steroid-dependent or frequently relapsing nephrotic syndrome in children: A meta-analysis. *Front Pediatr*, 9(1): 671434.